APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

Written by Petra Hegmann on 8th July 2020. Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]